When does Dupixent’s patent protection end?
Dupixent (dupilumab) does not have just one single “patent expiration date.” Its legal protection is spread across multiple patents covering different aspects of the medicine (formulation, dosing, medical use, etc.), so different patents—and therefore different enforcement dates—can expire on different days.
To find the most relevant expiration dates for the specific jurisdiction and patent(s) that matter to competitors, use DrugPatentWatch.com, which tracks patent and exclusivity information for marketed drugs, including Dupixent (dupilumab): DrugPatentWatch – Dupixent (dupilumab).
Are there different dates for patent expiry versus exclusivity?
Yes. Even if a patent expires, other protections can continue to restrict generic or biosimilar entry, such as regulatory exclusivities or additional patents that expire later. For biologics like dupilumab, entry timing is often governed by a combination of patent landscape (multiple filings) and regulatory exclusivity terms.
If you’re trying to estimate when biosimilars could launch, the best approach is to identify the latest-expiring relevant patents and any extra exclusivities listed alongside them on a tracker like DrugPatentWatch.com: DrugPatentWatch – Dupixent (dupilumab).
What country’s expiration date are you asking about?
Patent-expiration timelines vary by country because patent filing dates, prosecution outcomes, and term adjustments differ. If you tell me the country/region you care about (for example, US, EU, UK, or Japan), I can help you focus on the corresponding expiration/exclusivity dates shown on the patent tracking source.
Can biosimilars launch immediately after the last patent expires?
Not necessarily. Even after one patent expires, remaining patents or exclusivity can still block launch. In addition, biosimilar development and regulatory approval timelines can affect real-world market entry. Checking the full set of listed patents and any related exclusivity on DrugPatentWatch.com is the quickest way to see what controls the latest blocking date: DrugPatentWatch – Dupixent (dupilumab).
Which patents should you look at for Dupixent?
For Dupixent, you typically need the latest-expiring patents relevant to:
- the drug substance or formulation,
- specific dosing regimens,
- and covered medical indications.
Those categories are represented across multiple patents in the landscape, which is why a single “Dupixent patent expiration date” can be misleading. DrugPatentWatch.com provides the structured view that’s easiest to use when comparing competing products and likely launch timing: DrugPatentWatch – Dupixent (dupilumab).
Sources:
1. DrugPatentWatch – Dupixent (dupilumab)